Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intarcia Therapeutics, Inc.

http://www.intarcia.com

Latest From Intarcia Therapeutics, Inc.

Coronavirus Update: CureVac Joins mRNA Vaccines Competitors, Beijing In Lockdown Again

CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.

Coronavirus COVID-19 Companies

Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round

Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.

Financing Coronavirus COVID-19

Removal Of ‘Legal’ And ‘Implicit’ Terms Cleared Way For ICH Q12 Guideline

Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.

Manufacturing Quality

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Implantable Devices
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • BioMedicines, Inc.
    • PhaseGain Clinical Research, Inc.
    • Phoundry Pharmaceuticals
UsernamePublicRestriction

Register